73 related articles for article (PubMed ID: 27161705)
1. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.
Pinessi D; Foglieni C; Bugatti A; Moroni E; Resovi A; Ribatti D; Rusnati M; Giavazzi R; Colombo G; Taraboletti G
Thromb Res; 2016 Apr; 140 Suppl 1():S182. PubMed ID: 27161705
[TBL] [Abstract][Full Text] [Related]
2. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.
Foglieni C; Pagano K; Lessi M; Bugatti A; Moroni E; Pinessi D; Resovi A; Ribatti D; Bertini S; Ragona L; Bellina F; Rusnati M; Colombo G; Taraboletti G
Sci Rep; 2016 Mar; 6():23432. PubMed ID: 27000667
[TBL] [Abstract][Full Text] [Related]
3. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2).
Rusnati M; Borsotti P; Moroni E; Foglieni C; Chiodelli P; Carminati L; Pinessi D; Annis DS; Paiardi G; Bugatti A; Gori A; Longhi R; Belotti D; Mosher DF; Colombo G; Taraboletti G
Angiogenesis; 2019 Feb; 22(1):133-144. PubMed ID: 30168023
[TBL] [Abstract][Full Text] [Related]
4. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.
Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L
PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323
[TBL] [Abstract][Full Text] [Related]
5. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
6. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.
Colombo G; Margosio B; Ragona L; Neves M; Bonifacio S; Annis DS; Stravalaci M; Tomaselli S; Giavazzi R; Rusnati M; Presta M; Zetta L; Mosher DF; Ribatti D; Gobbi M; Taraboletti G
J Biol Chem; 2010 Mar; 285(12):8733-42. PubMed ID: 20056600
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
[TBL] [Abstract][Full Text] [Related]
9. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors.
Taraboletti G; Rusnati M; Ragona L; Colombo G
Oncotarget; 2010 Nov; 1(7):662-673. PubMed ID: 21317461
[TBL] [Abstract][Full Text] [Related]
11. Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.
Rusnati M; Bugatti A; Mitola S; Leali D; Bergese P; Depero LE; Presta M
Sensors (Basel); 2009; 9(8):6471-503. PubMed ID: 22454596
[TBL] [Abstract][Full Text] [Related]
12. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
[TBL] [Abstract][Full Text] [Related]
13. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity.
Guillonneau X; Tassin J; Berrou E; Bryckaert M; Courtois Y; Mascarelli F
J Cell Physiol; 1996 Jan; 166(1):170-87. PubMed ID: 8557766
[TBL] [Abstract][Full Text] [Related]
14. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.
Chua CC; Rahimi N; Forsten-Williams K; Nugent MA
Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627
[TBL] [Abstract][Full Text] [Related]
15. Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.
Rusnati M; Urbinati C; Bonifacio S; Presta M; Taraboletti G
Pharmaceuticals (Basel); 2010 Apr; 3(4):1241-1278. PubMed ID: 27713299
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor signaling pathway in endothelial cells is activated by BMPER to promote angiogenesis.
Esser JS; Rahner S; Deckler M; Bode C; Patterson C; Moser M
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):358-67. PubMed ID: 25503991
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis.
Hussain S; Slevin M; Matou S; Ahmed N; Choudhary MI; Ranjit R; West D; Gaffney J
Angiogenesis; 2008; 11(3):245-56. PubMed ID: 18330714
[TBL] [Abstract][Full Text] [Related]
18. A computational model of fibroblast growth factor-2 binding to endothelial cells under fluid flow.
Patel NS; Reisig KV; Clyne AM
Ann Biomed Eng; 2013 Jan; 41(1):154-71. PubMed ID: 22825797
[TBL] [Abstract][Full Text] [Related]
19. Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44.
Hibino S; Shibuya M; Hoffman MP; Engbring JA; Hossain R; Mochizuki M; Kudoh S; Nomizu M; Kleinman HK
Cancer Res; 2005 Nov; 65(22):10494-501. PubMed ID: 16288042
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis.
Presta M; Andrés G; Leali D; Dell'Era P; Ronca R
Eur Cytokine Netw; 2009 Jun; 20(2):39-50. PubMed ID: 19541589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
